

Rheumatech AS awarded Research Council grant

Oslo, October 2012

Rheumatech's goal is to develop a drug for the treatment of autoimmune disease without serious side effects and improve patients' quality of life. This drug will target the underlying mechanism that drives the autoimmune activity in white blood cells.

Rheumatech has been awarded an R&D grant from the User-driven Research based Innovation (BIA) program run by the Research Council of Norway.

We achieved a grant of 7.7 million NOK from BIA for 2012 - 2015. The grant will fund optimization of chemical compounds forming a basis for the development of drug candidates and preliminary testing in animal models. The main project partners are the University of Oslo and Oslo University Hospital. Further partners include research institutes and commercial entities in Norway and internationally.

We have successfully completed our High-Throughput Screening program and are pleased to announce that we are currently transforming promising hit compounds into lead series' after chemical optimization. The successful screening, identification of hits and initiation of subsequent optimization represents an important milestone for our company.

Halvor L. Holen, Ph.D.
Managing Director
Rheumatech AS